Skip to content
DraconiticResearch
Search Sources API
184,937 studies31 sourcesUpdated 10 min ago
Peer-reviewedLicence not statedJAMA Oncology

Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non−Small Cell Lung Cancer

  • Yongling Ji1
  • Qiwen Li2,3
  • Long Chen4
  • Qingsong Pang5
  • Ou Jiang6
  • Yuanyuan Chen2,3
  • Jin Wang1
  • Hong Ge7
  • Yufeng Cheng8
  • Rongrong Zhou9
  • Xiangjiao Meng10
  • Xuhong Min11
25 more authors
  • Hui Wang12
  • Haihua Yang13
  • Yue Xie14
  • Anping Zheng15
  • Jie Li16
  • Bing Xia17
  • Desheng Hu18
  • Xi Zhang19
  • Fang Peng20
  • Wenhui Li21
  • Baoqing Chen2,3
  • Rui Li2,3
  • Shuohan Zheng2,3
  • Ling Cai2,3
  • Shubi Li2,3
  • Yujin Xu1
  • Wei Feng1
  • Xiaojing Lai1
  • Liming Sheng1
  • Xiaojiang Sun1
  • Zhun Wang1
  • Min Fang1
  • Yang Yang1
  • Yin Yang1
  • Ming Chen2,3
21 affiliations
  1. 1Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Science, Hangzhou, China
  2. 2State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
  3. 3United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co, Ltd, Guangzhou, China
  4. 4Guangxi Medical University Cancer Hospital, Nanning, China
  5. 5Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin, China
  6. 6The Second People’s Hospital of Neijiang, Neijiang, China
  7. 7The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
  8. 8Qilu Hospital of Shandong University, Jinan, China
  9. 9Xiangya Hospital, Central South University, Changsha, China
  10. 10Cancer Hospital of Shandong First Medical University, Jinan, China
  11. 11Anhui Provincial Chest Hospital, Hefei, China
  12. 12Hunan Cancer Hospital, Changsha, China
  13. 13Taizhou Hospital, Linhai, China
  14. 14Chongqing University Cancer Hospital, Chongqing, China
  15. 15Anyang Cancer Hospital, Anyang, China
  16. 16Shanxi Cancer Hospital, Taiyuan, China
  17. 17Hangzhou First People’s Hospital, Hangzhou, China
  18. 18Hubei Cancer Hospital, Wuhan, China
  19. 19The Third Xiangya Hospital of Central South University, Changsha, China
  20. 20The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  21. 21Yunnan Provincial Cancer Hospital, Kunming, China
Read full textDOICite

Related

  1. Efficacy and Safety of Benmelstobart Plus Anlotinib in Advanced Endometrial Cancer: Results of a Multi-Cohort, Phase II Study (ETER200).
    Shanhui Liang, Xiaojun Chen, Ke Wang +38
    MedCommPeer-reviewedCC BYFull textObstetrics, gynaecology & paediatricsEurope PMC
  2. Comparative Evaluation of Concurrent Carboplatin-Paclitaxel Versus Cisplatin-Etoposide Chemoradiotherapy in Unresectable Non-small Cell Lung Cancer: A Prospective Randomized Study
    Yamini Kumar, Bala Venkat Subramanian, G V Deepthi +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Durvalumab completion and re-administration after grade 2 radiation pneumonitis following concurrent chemoradiotherapy for unresectable stage III NSCLC: a single-center real-world study
    Shuri Aoki, Ryo Ariyasu, Tatsuya Kamima +9
    BMC CancerPeer-reviewedCC BYFull textOncologyDOAJ
  4. Efficacy and safety of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer with gradual progression after first-line osimertinib therapy: a single-center retrospective cohort study
    Translational Lung Cancer ResearchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  5. A Systematic Review and Meta-Analysis: Does Molecular Hydrogen Exert Radioprotective Effects Without Compromising the Antitumor Efficacy of Radiotherapy or Concurrent Chemoradiotherapy?
    Yu Ivy Zhang, Michiko Miyakawa, Ayako Miyakawa
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{ji2026benmelstobart,
  title = {{Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non−Small Cell Lung Cancer}},
  author = {Yongling Ji and Qiwen Li and Long Chen and Qingsong Pang and Ou Jiang and Yuanyuan Chen and Jin Wang and Hong Ge and Yufeng Cheng and Rongrong Zhou and Xiangjiao Meng and Xuhong Min and Hui Wang and Haihua Yang and Yue Xie and Anping Zheng and Jie Li and Bing Xia and Desheng Hu and Xi Zhang and Fang Peng and Wenhui Li and Baoqing Chen and Rui Li and Shuohan Zheng and Ling Cai and Shubi Li and Yujin Xu and Wei Feng and Xiaojing Lai and Liming Sheng and Xiaojiang Sun and Zhun Wang and Min Fang and Yang Yang and Yin Yang and Ming Chen},
  journal = {JAMA Oncology},
  year = {2026},
  month = oct,
  doi = {10.1001/jamaoncol.2026.3918},
  url = {https://doi.org/10.1001/jamaoncol.2026.3918},
}
RIS
TY  - JOUR
TI  - Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non−Small Cell Lung Cancer
AU  - Yongling Ji
AU  - Qiwen Li
AU  - Long Chen
AU  - Qingsong Pang
AU  - Ou Jiang
AU  - Yuanyuan Chen
AU  - Jin Wang
AU  - Hong Ge
AU  - Yufeng Cheng
AU  - Rongrong Zhou
AU  - Xiangjiao Meng
AU  - Xuhong Min
AU  - Hui Wang
AU  - Haihua Yang
AU  - Yue Xie
AU  - Anping Zheng
AU  - Jie Li
AU  - Bing Xia
AU  - Desheng Hu
AU  - Xi Zhang
AU  - Fang Peng
AU  - Wenhui Li
AU  - Baoqing Chen
AU  - Rui Li
AU  - Shuohan Zheng
AU  - Ling Cai
AU  - Shubi Li
AU  - Yujin Xu
AU  - Wei Feng
AU  - Xiaojing Lai
AU  - Liming Sheng
AU  - Xiaojiang Sun
AU  - Zhun Wang
AU  - Min Fang
AU  - Yang Yang
AU  - Yin Yang
AU  - Ming Chen
PY  - 2026
DA  - 2026/10/29
JO  - JAMA Oncology
DO  - 10.1001/jamaoncol.2026.3918
UR  - https://doi.org/10.1001/jamaoncol.2026.3918
SN  - 2374-2437
SN  - 2374-2445
ER  -